Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306916507> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4306916507 endingPage "7963" @default.
- W4306916507 startingPage "7953" @default.
- W4306916507 abstract "ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospective chart review of 161 adult patients with melanoma treated with at least one cycle of ICI regimen in the adjuvant or metastatic setting: 129 patients received PD-1 inhibitor monotherapy and 32 received dual immunotherapy. Patients were grouped by duration of irAE: permanent (no complete resolution), long-term (resolution over a period ≥ 6 months), transient (resolution over a period < 6 months), or no irAEs. A total of 283 irAEs were reported in the whole patient population. Sixty-six (41.0%) patients developed permanent irAEs, fifteen (9.3%) experienced long-term irAEs as their longest-lasting toxicity, thirty-four (21.1%) developed transient irAEs only, and forty-six (28.6%) experienced no irAEs. Permanent irAEs occurred in 21 (65.6%) patients treated with dual immunotherapy and in 45 (34.9%) patients treated with monotherapy. The majority of permanent irAEs were endocrine-related (36.0%) or skin-related (32.4%). Grade 3-4 permanent irAEs occurred in 20 (12.4%) patients and included toxicities such as adrenal insufficiency, myocarditis, and myelitis. Fifty-three (32.9%) patients were still requiring treatment for long-term or permanent irAEs 6 months or more following the completion of ICI therapy, including twenty-four patients on thyroid hormone replacement and twenty-two on oral steroids. ICI treatment was temporarily interrupted for 64 (22.6%) irAEs and permanently discontinued due to irAEs in 38 patients (13.6% of irAEs, 23.6% of patients); additionally, 4 (2.5%) patients died of irAEs. Our findings show that ICI treatment in melanoma is associated with a wide range of toxicities that can be permanent and may have long-lasting impacts on patients, which should therefore be discussed when obtaining consent for treatment." @default.
- W4306916507 created "2022-10-21" @default.
- W4306916507 creator A5047792214 @default.
- W4306916507 creator A5056009334 @default.
- W4306916507 creator A5066794291 @default.
- W4306916507 creator A5078587754 @default.
- W4306916507 creator A5086588458 @default.
- W4306916507 date "2022-10-20" @default.
- W4306916507 modified "2023-09-26" @default.
- W4306916507 title "Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients" @default.
- W4306916507 cites W2019607817 @default.
- W4306916507 cites W2097995306 @default.
- W4306916507 cites W2100158834 @default.
- W4306916507 cites W2123363005 @default.
- W4306916507 cites W2133075384 @default.
- W4306916507 cites W2154441168 @default.
- W4306916507 cites W2263279668 @default.
- W4306916507 cites W2529373149 @default.
- W4306916507 cites W2560367415 @default.
- W4306916507 cites W2752227448 @default.
- W4306916507 cites W2797309423 @default.
- W4306916507 cites W3131096095 @default.
- W4306916507 cites W3137634582 @default.
- W4306916507 cites W4210370153 @default.
- W4306916507 cites W4226360696 @default.
- W4306916507 doi "https://doi.org/10.3390/curroncol29100629" @default.
- W4306916507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36290906" @default.
- W4306916507 hasPublicationYear "2022" @default.
- W4306916507 type Work @default.
- W4306916507 citedByCount "5" @default.
- W4306916507 countsByYear W43069165072023 @default.
- W4306916507 crossrefType "journal-article" @default.
- W4306916507 hasAuthorship W4306916507A5047792214 @default.
- W4306916507 hasAuthorship W4306916507A5056009334 @default.
- W4306916507 hasAuthorship W4306916507A5066794291 @default.
- W4306916507 hasAuthorship W4306916507A5078587754 @default.
- W4306916507 hasAuthorship W4306916507A5086588458 @default.
- W4306916507 hasBestOaLocation W43069165071 @default.
- W4306916507 hasConcept C121608353 @default.
- W4306916507 hasConcept C126322002 @default.
- W4306916507 hasConcept C141071460 @default.
- W4306916507 hasConcept C187212893 @default.
- W4306916507 hasConcept C197934379 @default.
- W4306916507 hasConcept C2777658100 @default.
- W4306916507 hasConcept C2777701055 @default.
- W4306916507 hasConcept C2778129406 @default.
- W4306916507 hasConcept C2780580376 @default.
- W4306916507 hasConcept C2781413609 @default.
- W4306916507 hasConcept C2781433595 @default.
- W4306916507 hasConcept C2908647359 @default.
- W4306916507 hasConcept C502942594 @default.
- W4306916507 hasConcept C71924100 @default.
- W4306916507 hasConcept C99454951 @default.
- W4306916507 hasConceptScore W4306916507C121608353 @default.
- W4306916507 hasConceptScore W4306916507C126322002 @default.
- W4306916507 hasConceptScore W4306916507C141071460 @default.
- W4306916507 hasConceptScore W4306916507C187212893 @default.
- W4306916507 hasConceptScore W4306916507C197934379 @default.
- W4306916507 hasConceptScore W4306916507C2777658100 @default.
- W4306916507 hasConceptScore W4306916507C2777701055 @default.
- W4306916507 hasConceptScore W4306916507C2778129406 @default.
- W4306916507 hasConceptScore W4306916507C2780580376 @default.
- W4306916507 hasConceptScore W4306916507C2781413609 @default.
- W4306916507 hasConceptScore W4306916507C2781433595 @default.
- W4306916507 hasConceptScore W4306916507C2908647359 @default.
- W4306916507 hasConceptScore W4306916507C502942594 @default.
- W4306916507 hasConceptScore W4306916507C71924100 @default.
- W4306916507 hasConceptScore W4306916507C99454951 @default.
- W4306916507 hasIssue "10" @default.
- W4306916507 hasLocation W43069165071 @default.
- W4306916507 hasLocation W43069165072 @default.
- W4306916507 hasLocation W43069165073 @default.
- W4306916507 hasLocation W43069165074 @default.
- W4306916507 hasOpenAccess W4306916507 @default.
- W4306916507 hasPrimaryLocation W43069165071 @default.
- W4306916507 hasRelatedWork W2003938723 @default.
- W4306916507 hasRelatedWork W2047967234 @default.
- W4306916507 hasRelatedWork W2118496982 @default.
- W4306916507 hasRelatedWork W2353498344 @default.
- W4306916507 hasRelatedWork W2429247496 @default.
- W4306916507 hasRelatedWork W2439875401 @default.
- W4306916507 hasRelatedWork W2981745426 @default.
- W4306916507 hasRelatedWork W4238867864 @default.
- W4306916507 hasRelatedWork W4280556106 @default.
- W4306916507 hasRelatedWork W2525756941 @default.
- W4306916507 hasVolume "29" @default.
- W4306916507 isParatext "false" @default.
- W4306916507 isRetracted "false" @default.
- W4306916507 workType "article" @default.